Entheogens and psychedelics in Canada: Proposal for a new paradigm.

Rochester, Jessica; Vallely, Anne; Grof, Paul; Williams, Monnica T.; Chang, Harvey; Caldwell, Kate

doi:10.1037/cap0000285

Cited by 15 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We see very similar issues and challenges facing the Australian clinical community to those identified in Canada by Rochester and colleagues (37). Based on these similarities, we see merit in recommending an Advisory Committee that draws upon the expertise of the medical colleges and professional associations, alongside academic institutions, cultural groups, regulators, and the broader community.…”

Section: Discussion and Recommendationsmentioning

confidence: 64%

“…Our recommendation is inspired by the recent proposal of a National Advisory Council and subsidiary Credentialing Council to undertake strategic oversight of psychedelic therapies in Canada (37). In the Canadian model, those councils would advise on, inter alia, ethical codes of conduct, education and training, core clinical competencies, and accreditation of clinicians and practitioners to provide psychedelic-assisted therapies to clients.…”

Section: Discussion and Recommendationsmentioning

confidence: 99%

“…We recommend the foundation of a dedicated crossdisciplinary professional body to oversee the field, given the broad range of backgrounds from which psychedelic therapists will be drawn. The Canadian model of a Credentialing Council (37) would provide a good starting point for our proposed Accreditation Committee, which we see taking a supporting role to that of the Advisory Committee on Psychedelic Therapies.…”

Section: Training and Accreditationmentioning

confidence: 99%

See 2 more Smart Citations

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

et al. 2021

View full text Add to dashboard Cite

Research exploring the potential of psychedelic-assisted therapies to treat a range of mental illnesses is flourishing, after the problematic sociopolitical history of psychedelics led to the shutdown of clinical research for almost 40 years. Encouraged by positive results, clinicians and patients are now hopeful that further interruptions to research will be avoided, so that the early promise of these therapies might be fulfilled. At this early stage of renewed interest, researchers are understandably focusing more on clinical trials to investigate safety and efficacy, than on longer-term goals such as progression to community practice. Looking to identify and avoid potential pitfalls on the path to community clinics, the authors, a group of Australian clinicians and researchers, met to discuss possible obstacles. Five broad categories of challenge were identified: 1) inherent risks; 2) poor clinical practice; 3) inadequate infrastructure; 4) problematic perceptions; and 5) divisive relationships and fractionation of the field. Our analysis led us to propose some strategies, including public sector support of research and training to establish best practice and optimize translation, and funding to address issues of equitable access to treatment. Above all, we believe that strategic planning and professional cohesion will be crucial for success. Accordingly, our key recommendation is the establishment of a multidisciplinary advisory body, broadly endorsed and representing all major stakeholders, to guide policy and implementation of psychedelic-assisted therapies in Australia. Although these challenges and strategies are framed within the Australian context, we sense that they may generalize to other parts of the world. Wherever they apply, we believe that anticipation of potential difficulties, and creative responses to address them, will be important to avoid roadblocks in the future and keep the “psychedelic renaissance” on track.

show abstract

Section: Discussion and Recommendationsmentioning

confidence: 64%

Section: Discussion and Recommendationsmentioning

confidence: 99%

Section: Training and Accreditationmentioning

confidence: 99%

See 1 more Smart Citation

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Formal guidelines, curricula and training-devised in conjunction with regulators and organisations that educate and support psychiatrists-will be needed before psychiatrists will feel ready to participate in the delivery of this promising new treatment paradigm. For example, a multi-disciplinary group from Canada recently recommended that a National Advisory Council be created to make recommendations and around training and accreditation for clinicians involved in the provision of PAP there (19). In summary, however strong the research evidence for the efficacy of PAP in psychiatric disorders, our findings suggest this will be insufficient for PAP to be implemented within NHS mental health services without considerable attention on the workforce needed to deliver it.…”

Section: Study Strengths and Weaknessesmentioning

confidence: 78%

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy

et al. 2021

View full text Add to dashboard Cite

Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients. This pilot study examined the attitudes and knowledge of NHS psychiatrists of all levels towards psychedelic-assisted psychotherapy and explored potential barriers and facilitators to its implementation.Methods: A mixed-methods approach was adopted, using a cross-sectional survey and focus groups. All psychiatrists in one NHS mental health trust were approached by email to participate. The survey was analysed using a simple descriptive approach and thematic analysis was used for the focus groups.Results: Eighty-three (25.7%) psychiatrists participated in the survey. All psychiatrists were familiar with one or more psychedelic substances. Although 77.2% felt that there should be a role for controlled or therapeutic use of psychedelics, trainees appeared better informed than non-training grade psychiatrists. Psychiatrists of all grades did not feel prepared to participate in the delivery of psychedelic-assisted psychotherapy. Thematic analysis of the focus groups identified three main themes in relation to psychedelic-assisted psychotherapy: “need for knowledge,” “openness to change,” and “uncertainty.”Discussion: NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise. However, psychiatrists are lacking in confidence or preparedness to implement this treatment should it become a mainstream option and significant training needs were identified. Thematic analysis highlighted the need for societal shifts as well as professional ones.

show abstract

“…Psychedelic research necessarily brings with it political entanglements. In Canada, a team of six appointed experts, including Religious Studies scholar Anne Vallely, recently submitted a report to the government detailing recommendations for the safe implementation of psychedelic use (Rochester et al 2021). In the United States, political prospects for psychedelic drugs seem more doubtful, at least in the short term.…”

mentioning

confidence: 99%

Psychedelic Drugs and Atheism: Debunking the Myths

Glausser

2021

Religions

View full text Add to dashboard Cite

Two recent surveys of people who took psychedelic drugs and reported “God experience encounters”, along with successful clinical trials using psychedelic therapy for depression, have given rise to public misconceptions about psychedelics and atheism. Specifically, three inferences have been drawn: (1) that the psychedelic experience tends to dissolve atheist convictions; (2) that atheist convictions, once dissolved, are replaced with traditional monotheist beliefs; and (3) that atheism and depression somehow correlate as afflictions for which psychedelic drugs offer relief. This paper argues, based on analysis of the studies and trials along with relevant supplemental evidence, that each of these popular inferences is substantially misleading. Survey data do not indicate that most psychedelic atheists have cleanly cut ties with their former convictions, and there is strong evidence that they have not traded atheism for traditional monotheism. Both personal testimony and the effectiveness of microdose clinical trials serve to complicate any notion that a psychedelic drug alleviates symptoms of depression by “curing” atheism. The paper then extends its focus to argue that the broader field of neurotheology includes elements that contribute to these popular misconceptions.

show abstract

Entheogens and psychedelics in Canada: Proposal for a new paradigm.

Cited by 15 publications

References 73 publications

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy

Psychedelic Drugs and Atheism: Debunking the Myths

Contact Info

Product

Resources

About